IN8bio is the first company to advance genetically modified gamma-delta T cells in to the clinic using our DeltEx Platform, based on ex vivo expanded and activated gamma-delta T cells, our biological expertise, proprietary genetic engineering and cell-type specific manufacturing.

IN8bio is located in New York City with its primary scientific operations in Birmingham, Alabama.

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.

IN8Bio Inc. products

Technology

IN8Bio DeltEx - Gamma-Delta T Cells